Bayraktar Ulas D, Milton Denái R, Guindani Michele, Rondon Gabriela, Chen Julianne, Al-Atrash Gheath, Rezvani Katayoun, Champlin Richard, Ciurea Stefan O
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; Division of Hematology and Medical Oncology, Memorial Sisli Hospital, Istanbul, Turkey.
Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Biol Blood Marrow Transplant. 2016 Mar;22(3):505-13. doi: 10.1016/j.bbmt.2015.10.020. Epub 2015 Oct 31.
The recovery pace of absolute lymphocyte count (ALC) is prognostic after hematopoietic stem cell transplantation. Previous studies have evaluated a wide range of ALC cutoffs and time points for predicting outcomes. We aimed to determine the optimal ALC value for outcome prediction after bone marrow transplantation (BMT). A total of 518 patients who underwent BMT for acute leukemia or myelodysplastic syndrome between 1999 and 2010 were divided into a training set and a test set to assess the prognostic value of ALC on days 30, 60, 90, 120, 180, as well as the first post-transplantation day of an ALC of 100, 200, 300, 400, 500, and 1000/μL. In the training set, the best predictor of overall survival (OS), relapse-free survival (RFS), and nonrelapse mortality (NRM) was ALC on day 60. In the entire patient cohort, multivariable analyses demonstrated significantly better OS, RFS, and NRM and lower incidence of graft-versus-host disease (GVHD) in patients with an ALC >300/μL on day 60 post-BMT, both including and excluding patients who developed GVHD before day 60. Among the patient-, disease-, and transplant-related factors assessed, only busulfan-based conditioning was significantly associated with higher ALC values on day 60 in both cohorts. The optimal ALC cutoff for predicting outcomes after BMT is 300/μL on day 60 post-transplantation.
造血干细胞移植后,绝对淋巴细胞计数(ALC)的恢复速度具有预后价值。以往研究评估了多种用于预测结局的ALC临界值和时间点。我们旨在确定骨髓移植(BMT)后用于结局预测的最佳ALC值。1999年至2010年间接受BMT治疗急性白血病或骨髓增生异常综合征的518例患者被分为训练集和测试集,以评估移植后第30、60、90、120、180天以及ALC分别为100、200、300、400、500和1000/μL时首个移植后日的ALC的预后价值。在训练集中,总生存(OS)、无复发生存(RFS)和非复发死亡率(NRM)的最佳预测指标是移植后第60天的ALC。在整个患者队列中,多变量分析显示,BMT后第60天ALC>300/μL的患者,无论是否包括在第60天前发生移植物抗宿主病(GVHD)的患者,其OS、RFS和NRM均显著更好,且GVHD发生率更低。在评估的患者、疾病和移植相关因素中,仅白消安预处理与两个队列中第60天较高的ALC值显著相关。BMT后预测结局的最佳ALC临界值是移植后第60天的300/μL。